source
- FDA places partial hold on Biohaven epilepsy drug BHV-7000 amid $350 million licensing dealThe U.S. Food and Drug Administration issued a partial clinical hold on enrollment for Biohaven’s epilepsy candidate BHV-7000 after rodent studies raised questions about drug metabolites. The hold…
- Takeda R&D chief Andy Plump to retire after string of recent FDA approvalsTakeda's long-serving research and development president Andy Plump will step down in June. He joined the Japanese drugmaker in 2015 from Sanofi and has led the R&D organization since then. His ex…